TFEB silencing impairs cholesterol homeostasis by inhibiting ERK1/2/SREBP2 axis and ABCA1/IPP/Vγ9Vδ2 T-cell-mediated immuno-killing of non-small cell lung cancer cells. This evidence concerns the gene MAPK3 and non-small cell lung carcinoma.